RxDoctor Payments DataLook up a doctor →

Erin Petrusic

Psychiatric/Mental Health · Chicago, ILNPI 1124432497

Payments from drug & device makers

$517,041in general payments, 2019–2025

Across 888 payments — averaging $582.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurocrine Biosciences, Inc.$480K
  • AbbVie$25K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$6K
  • E.r. Squibb & Sons, L.L.C.$2K
  • Alkermes, Inc.$874
  • Teva Pharmaceuticals USA, Inc.$856
  • plus $3K from 15 others

What the payments were for

  • Consulting fees$32,4886%
  • Speaking & faculty fees$415,20780%
  • Travel & lodging$48,4559%
  • Food & beverage$20,6224%
  • Education$2690%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$517,041 in reported general payments places this provider in the 95th percentile of 922 psychiatric/mental health providers in Illinois.

See all psychiatric/mental health providers in Illinois

Medicare billing

Part B allowed, 2024
$4,442
Medicare patients
16
Services billed
52

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate26$202,431
LybalviOlanzapine/Samidorphan Malate18$27,512
TrintellixVortioxetine Hydrobromide20$9,371
Desvenlafaxine Succinate ErDesvenlafaxine Succinate14$1,039
Clozapine11$235
Alprazolam13$217
Trazodone Hcl29$166
Aripiprazole14$129
Clonazepam11$85
Mirtazapine15$57
Lamotrigine12$32

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$479,667$202,43126 claims
Alkermes, Inc.Lybalvi$874$27,51218 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$109$9,37120 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 922 psychiatric/mental health providers in Illinois.

Other psychiatric/mental health in Chicago

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →